Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026)
Climb Bio (CLYM) reported Non Operating Investment Income of -$278000.0 for Q1 2026, down 205.7% on a YoY basis from $263000.0 in Q1 2025, and down 717.65% quarter-over-quarter from -$34000.0 in Q4 2025.
Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026) Analysis & Trends
Climb Bio has reported Non Operating Investment Income for 6 years, with the latest figure at -$278000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income fell 205.7% year-over-year to -$278000.0; the trailing twelve-month figure through Mar 2026 stood at -$129000.0 (down 145.1% YoY), and the FY2025 full-year result was $412000.0, up 1548.0% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$278000.0, down from -$34000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $263000.0 in Q1 2023, with the low at -$398000.0 in Q1 2022.
- Historically, Non Operating Investment Income has averaged $17500.0 across 5 years, with a median of $23500.0 in 2022.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income slumped 2077.78% — and 2025, when it surged 13050.0%.
- Climb Bio's Non Operating Investment Income stood at $223000.0 in 2022, then plunged by 95.96% to $9000.0 in 2023, then tumbled by 2077.78% to -$178000.0 in 2024, then jumped by 80.9% to -$34000.0 in 2025, then sank by 717.65% to -$278000.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$278000.0 (Q1 2026), -$34000.0 (Q4 2025), and $151000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | -278,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -278,000.00 |
| Mar 31, 2026 | -278,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | -178,000.00 |
| Dec 31, 2024 | -178,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 24,000.00 |
| Sep 30, 2023 | 24,000.00 |